News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Dana responded well to the experimental drug nirogacestat for her desmoid tumor – Memorial Sloan Kettering Cancer Center
Photo taken from mskcc.org
Dec 7, 2023, 03:21

Dana responded well to the experimental drug nirogacestat for her desmoid tumor – Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center shared on their LinkedIn:

“ICYMI: On November 27, the U.S. Food and Drug Administration approved nirogacestat (Ogsiveo™) for adults with desmoid tumors that cannot be treated with surgery alone. The approval was based on research led by investigators at MSK. Nirogacestat is the first targeted therapy ever to be approved for desmoid tumors.

Dana, shown here with her husband, John, has responded well to the experimental drug nirogacestat for her desmoid tumor. Learn more about her care from MSK’s sarcoma expert Mrinal Gounder here. ”

Source: Memorial Sloan Kettering Cancer Center/LinkedIn

cancer desmoid tumors Food and Drug Administration Memorial Sloan Kettering Cancer Center Mrinal Gounder MSK nirogacestat Ogsiveo OncoDaily Oncology
Special Coverage
Voices
Aug 21, 2025, 15:59
George Kumar: The interplay Between Cardiovascular Disease (CVD) and Cancer
Voices
Aug 21, 2025, 15:47
European Society of Gynaecological Oncology Announces that Applications are Open for Editor-in-Chief of IJGC
Insight
Aug 21, 2025, 15:37
Carolina Reduzzi: ctDNA Landscape Analysis Post CDK4/6 Inhibitor in HR+/HER2- Metastatic Breast Cancer
Voices
Aug 21, 2025, 15:30
Clinician-Scientists Awarded NMRC Transition Awards for Precision Lung Cancer Research - National Cancer Centre Singapore
Voices
Aug 21, 2025, 15:22
Construction of the $658 million Sydney Children’s Hospital Stage One and MCCCC Project Has Reached Completion
Oncolibrary
Aug 21, 2025, 15:00
Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule
Voices
Aug 21, 2025, 14:50
Andrea Apolo Highlights the Top 5 Clinical Advances in Bladder Cancer Treatment for 2024
Insight
Aug 21, 2025, 14:47
Loay Kassem: Study Reveals BRCA Mutation Rates in Egyptian Women with Breast or Ovarian Cancer
Insight
Aug 21, 2025, 14:41
Tiago Cordeiro Felismino: Exploring the Role of Neutrophil-to-Lymphocyte Ratio in Advanced HCC Treatment
Voices
Aug 21, 2025, 14:40
Larissa Nekhlyudov Celebrates Leadership of Emily Smith Tonorezos and Michelle Mollica in Cancer Survivorship
Voices
Aug 21, 2025, 14:32
Hayley Jones: McCabe Centre Supports Daffodil Day with 38,000 Daffodils for Cancer Awareness
Voices
Aug 21, 2025, 14:26
Chrystal Paulos: Exciting Opportunities to Build with the Paulos Lab at Winship Cancer Institute